EU regulators back climate-friendly inhaler
Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD).
These types of inhalers may be small, but they pack a powerful punch, producing the same type of greenhouse gas as air conditioning and heat pumps. In the United Kingdom, they cause 3 per cent of the National Health Service's (NHS) overall carbon emissions, according to Asthma + Lung UK.
Many of these gases are now being phased out in the EU for environmental reasons, according to the European Medicines Agency (EMA).
An EMA advisory committee issued a positive opinion of the new inhaler on Friday, and the European Commission, the EU's executive body, will make a final decision in the coming months.
Other inhalers that do not use gas propellants are already available, and AstraZeneca's new model has a similarly low carbon footprint.
The new option 'means patients and their clinicians now don't need to feel like they have to choose between the most appropriate treatment and the planet,' Pablo Panella, AstraZeneca's senior vice president of global respiratory and immunology, said in a written comment to Euronews Health.
The new inhaler is already available in the United States, China, and Japan, and the United Kingdom signed off in May.
AstraZeneca said it plans to transition its inhalers to the new model across the EU in the coming months, and that it hopes to roll the model out worldwide by 2030.
The EMA said it 'works the same way and gives the same results in the lungs and the body [as] the product currently on the market'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
3 hours ago
- France 24
French court rules Bayer not liable in landmark glyphosate birth defect case
A French court ruled on Thursday that a complaint brought by a family against Bayer claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissible, local media reported. Bayer, which produces the herbicide, said it acknowledged the court's decision, 'which did not find the company liable'. Lawyers for the Grataloup family said: 'It is clearly a big disappointment for the Grataloup family and for us ... The case deserves to be submitted to the appeals court.' The lawsuit was one of the first high-profile cases centring specifically on prenatal exposure to glyphosate and congenital malformations in a child. Research has suggested prenatal exposure to glyphosate may affect babies' health at birth, but successful lawsuits have been rare. Bayer has said the product is safe for human use. The German pharmaceutical and biotechnology group has paid around $10 billion to settle disputed claims in the United States that its weedkiller Roundup, based on glyphosate, causes cancer. The European Union last renewed the approval of the use of glyphosate in 2023, through December 2033.
Euronews
4 hours ago
- Euronews
Germany to allow some depressed patients to try psychedelics
Germany's medicine regulator will allow certain patients with treatment-resistant depression to try psilocybin therapy, a major shift as psychedelics inch closer to mainstream medicine. It is the first time in the European Union that psilocybin – the hallucinogenic compound in magic mushrooms – will be made available through a compassionate use scheme, in which patients with serious or life-threatening illnesses can get access to drugs that have not yet been approved. In Germany, psilocybin will only be prescribed in 'justified exceptional cases,' according to the Central Institute of Mental Health (CIMH), which asked regulators to greenlight the programme. 'This is an enormously important step that expands our scope for action,' Dr Gerhard Gründer, head of CIMH's molecular neuroimaging department, said in a statement. In some cases, psilocybin therapy 'can be a medically and ethically justifiable option, provided it is carried out under strictly controlled conditions and with careful medical supervision,' Gründer added. Depression is a common mental health problem, but approximately 20 per cent to 30 per cent of people with depression do not respond well to standard treatments, CIMH said. Studies have shown that psilocybin could be a promising alternative for these patients. The drug is thought to foster connections between different regions of the brain, helping people let go of excessive self-focus and rumination, according to scientists from the United Kingdom and United States. But sceptics have warned that studies on psychedelic drugs can be hard to replicate. Growing interest in psychedelics The decision from Germany's Federal Institute for Drugs and Medical Devices (BfArM) reflects growing interest in psychedelic therapies, including psilocybin and MDMA, as a treatment for mental health issues such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). Earlier this month, the Czech Republic legalised the medical use of psilocybin for conditions such as depression. Meanwhile, the first EU-funded trial on psychedelic medicines launched last year to test whether psilocybin can alleviate anxiety and depression among patients with progressive diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Other clinical trials are also underway in Europe, including in Germany, though full approval for psilocybin is not expected in Germany for several years. In the meantime, the Psychedelic Access And Research European Alliance (PAREA), a nonprofit advocacy group, said compassionate use programmes can complement clinical trials by offering real-world data on these treatments and ensuring they are available for 'patients who cannot wait' for full approval. CIMH expects that many patients will be interested in Germany's limited access scheme. 'Experience from Switzerland shows that demand far exceeds the available supply,' Gründer said. 'We must therefore continue to work on bringing psychedelics such as psilocybin into standard care for the treatment of mental illness,' he added.
Euronews
a day ago
- Euronews
$10M in US-funded contraceptives sit in limbo in Europe
Millions of dollars' worth of US-funded contraceptives which have been sitting in storage for months in a Belgian warehouse face destruction amid a controversy over whether they can be spared for distribution to the needy. The stash is reported to include more than 50,000 intrauterine devices, nearly two million doses of injectable contraceptives, and more than two million packets of oral birth control, and is being kept in the small city of Geel near Antwerp. The contraceptive products were originally intended for distribution to lower-income countries by the now dismantled United States Agency for International Development (USAID). Following the dissolution of USAID - whose aim was to improve health, reduce poverty, and promote human rights and democracy in low-income nations - many international projects and partnerships have been abandoned. The US government's current plan for the contraceptives left in limbo in Geel is to incinerate them—despite their expiration date being between 2027 and 2031. This isn't the first time the American government has opted for such a drastic solution. After budget cuts, food rations capable of feeding 3.5 million people for a month were reportedly left to rot in warehouses around the world, as documented by Reuters. The decision to destroy the contraceptive supplies has drawn sharp criticism from civil society groups. 'It's the height of hypocrisy for a government to preach efficiency and cutting waste, only to turn around and recklessly destroy life-saving supplies when the need has never been greater. This isn't just inefficient — it's unconscionable,' said Micah Grzywnowicz, regional director of International Planned Parenthood Federation's European network. IPPF publicly offered to collect the supplies from Geel, repackage them in its warehouse in the Netherlands, and distribute them to women in need across the globe, 'all at no cost to the US government', according to Grzywnowicz. Several other organisations, including the United Nations Population Fund (UNFPA) and the global charity MSI Reproductive Choices, have also expressed willingness to purchase or redistribute the stockpiles. All offers have reportedly been rejected by the Trump administration. The Belgian government also confirmed to Euronews it is in contact with the US embassy in Brussels. 'The Ministry of Foreign Affairs is exploring all possible avenues to prevent the destruction of these stocks, including their temporary relocation,' a spokesperson told Euronews. As the supplies are reportedly set to be removed to France for destruction, politicians from the French Green Party, Les Écologistes, have appealed to President Emmanuel Macron to intervene. 'We cannot allow Donald Trump's anti-choice agenda to unfold on our territory. And so today, France must mediate with the Commission,' MEP Mélissa Camara (France/The Greens), one of the signatories of the letter, told Euronews. She added that the destruction of these contraceptives would endanger women around the world, especially in Africa, the original destination of the supplies. Camara has also addressed a separate letter to European Commission President Ursula von der Leyen and other members of the Commission, including Commissioner Hadja Lahbib, whose portfolio includes sexual and reproductive health and rights. A spokesperson told Euronews that the European Commission had 'taken note of the letters and acknowledge the concerns raised'. They added that the EU remains strongly committed to promoting sexual and reproductive health and rights (SRHR), including family planning, and that investment in SRHR is a key contributor to social and economic development. 'We continue to monitor the situation closely to explore the most effective solutions,' the spokesperson said.
